Randomized trial of primaquine hypnozoitocidal efficacy when administered with artemisinin-combined blood schizontocides for radical cure of Plasmodium vivax in Indonesia

BMC Medicine

Volumn 13, Issue 1, 2015, Pages

  Nelwan, Erni J ^a   Ekawati, Lenny L ^b   Tjahjono, Bagus ^c   Setiabudy, Rianto ^a   Sutanto, Inge ^a   Chand, Krisin ^b   Ekasari, Tyas ^b   Djoko, Dwi ^c   Basri, Hasan ^b   Taylor, W Robert ^b   Duparc, Stephan ^d   Subekti, Decy ^b   Elyazar, Iqbal ^b   Noviyanti, Rintis ^e   Sudoyo, Herawati ^e   Baird, J Kevin ^b,f  

^a UNIVERSITY OF INDONESIA   (Indonesia)

^b OXFORD UNIVERSITY CLINICAL RESEARCH UNIT   (Viet Nam)

^c Municipal Health Service   (Indonesia)

^d Medicines for Malaria Venture   (Switzerland)

^e EIJKMAN INSTITUTE FOR MOLECULAR BIOLOGY   (Indonesia)

^f UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Efficacy; Malaria; Plasmodium vivax; Primaquine; Relapse

Indexed keywords

ARTESUNATE; ARTESUNATE PLUS PYRONARIDINE; DIHYDROARTEMISININ PLUS PIPERAQUINE; PRIMAQUINE; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; FOLLOW UP; HUMAN; INDONESIA; INDONESIAN; MAJOR CLINICAL STUDY; PARASITEMIA; PLASMODIUM VIVAX MALARIA; RANDOMIZED CONTROLLED TRIAL; RECURRENT INFECTION; RELAPSE; SOLDIER; COMBINATION DRUG THERAPY; FEMALE; MALARIA, VIVAX; MALE; PLASMODIUM VIVAX; RECURRENT DISEASE;

ADULT; ANTIMALARIALS; ARTEMISININS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INDONESIA; MALARIA, VIVAX; MALE; MILITARY PERSONNEL; PLASMODIUM VIVAX; PRIMAQUINE; RECURRENCE;

EID: 84952870456     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/s12916-015-0535-9     Document Type: Article

References (44)

1. Gething PW, Elyazar IR, Moyes CL, Smith DL, Battle KE, Guerra CA, et al. A long neglected world malaria map: Plasmodium vivax endemicity in 2010. PLoS Negl Trop Dis. 2012;6(9):e1814.
2. Baird JK. Evidence and implications of mortality associated with acute Plasmodium vivax malaria. Clin Microbiol Rev. 2013;26(1):36-57.
3. Tjitra E, Anstey NM, Sugiarto P, Warikar N, Kenangalem E, Karyana M, et al. Multidrug-resistant Plasmodium vivax associated with severe and fatal malaria: a prospective study in Papua, Indonesia. PLoS Med. 2008;5(6):e128.
4. Battle KE, Karhunen MS, Bhatt S, Gething PW, Howes RE, Golding N, et al. Geographical variation in Plasmodium vivax relapse. Malar J. 2014;13:144.
5. Coatney GR, Cooper WC, Young MD. Studies in human malaria. XXX. A summary of 204 sporozoite-induced infections with the Chesson strain of Plasmodium vivax. J Natl Malar Soc. 1950;9(4):381-96.
6. Douglas NM, Nosten F, Ashley EA, Phaiphun L, van Vugt M, Singhasivanon P, et al. Plasmodium vivax recurrence following falciparum and mixed species malaria: risk factors and effect of antimalarial kinetics. Clin Infect Dis. 2011;52(5):612-20.
7. Sutanto I, Tjahjono B, Basri H, Taylor WR, Putri FA, Meilia RA, et al. Randomized, open-label trial of primaquine against vivax malaria relapse in Indonesia. Antimicrob Agents Chemother. 2013;57(3):1128-35.
8. Betuela I, Rosanas-Urgell A, Kiniboro B, Stanisic DI, Samol L, de Lazzari E, et al. Relapses contribute significantly to the risk of Plasmodium vivax infection and disease in Papua New Guinean children 1-5 years of age. J Infect Dis. 2012;206(11):1771-80.
9. White MT, Karl S, Battle KE, Hay SI, Mueller I, Ghani AC. Modelling the contribution of the hypnozoite reservoir to Plasmodium vivax transmission. Elife. 2014; 3. Doi:10.7554/eLife.04692
10. Llanos-Cuentas A, Lacerda MV, Rueangweerayut R, Krudsood S, Gupta SK, Kochar SK, et al. Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study. Lancet. 2014;383(9922):1049-58.
11. Price RN, von Seidlein L, Valecha N, Nosten F, Baird JK, White NJ. Global extent of chloroquine-resistant Plasmodium vivax: a systematic review and meta-analysis. Lancet Infect Dis. 2014;14(10):982-91.
12. Kusriastuti R, Surya A. New treatment policy of malaria as a part of malaria control program in Indonesia. Acta Med Indones. 2012;44(3):265-9.
13. rd edition. Geneva: WHO; 2015. p. 317.
14. U.S. Centers for Disease Control. CDC Health Information for International Travel 2014. New York, New York, USA: Oxford University Press; 2014.
15. Baird JK. Resistance to chloroquine unhinges vivax malaria therapeutics. Antimicrob Agents Chemother. 2011;55(5):1827-30.
16. Hanboonkunupakarn B, Ashley EA, Jittamala P, Tarning J, Pukrittayakamee S, Hanpithakpong W, et al. Open-label crossover study of primaquine and dihydroartemisinin-piperaquine pharmacokinetics in healthy adult thai subjects. Antimicrob Agents Chemother. 2014;58(12):7340-6.
17. Jittamala P, Pukrittayakamee S, Ashley EA, Nosten F, Hanboonkunupakarn B, Lee SJ, et al. Pharmacokinetic interactions between primaquine and pyronaridine-artesunate in healthy adult Thai subjects. Antimicrob Agents Chemother. 2015;59(1):505-13.
18. Gogtay N, Kannan S, Thatte UM, Olliaro PL, Sinclair D. Artemisinin-based combination therapy for treating uncomplicated Plasmodium vivax malaria. Cochrane Database Syst Rev. 2013;10:CD008492.
19. Phyo AP, Lwin KM, Price RN, Ashley EA, Russell B, Sriprawat K, et al. Dihydroartemisinin-piperaquine versus chloroquine in the treatment of Plasmodium vivax malaria in Thailand: a randomized controlled trial. Clin Infect Dis. 2011;53(10):977-84.
20. Poravuth Y, Socheat D, Rueangweerayut R, Uthaisin C, Pyae Phyo A, Valecha N, et al. Pyronaridine-artesunate versus chloroquine in patients with acute Plasmodium vivax malaria: a randomized, double-blind, non-inferiority trial. PLoS One. 2011;6(1):e14501.
21. Croft SL, Duparc S, Arbe-Barnes SJ, Craft JC, Shin CS, Fleckenstein L, et al. Review of pyronaridine anti-malarial properties and product characteristics. Malar J. 2012;11:270.
22. Hamedi Y, Safa O, Zare S, Tan-ariya P, Kojima S, Looareesuwan S. Therapeutic efficacy of artesunate in Plasmodium vivax malaria in Thailand. Southeast Asian J Trop Med Public Health. 2004;35(3):570-4.
23. Alving AS, Arnold J, Hockwald RS, Clayman CB, Dern RJ, Beutler E, et al. Potentiation of the curative action of primaquine in vivax malaria by quinine and chloroquine. J Lab Clin Med. 1955;46(2):301-6.
24. Elyazar IR, Gething PW, Patil AP, Rogayah H, Sariwati E, Palupi NW, et al. Plasmodium vivax malaria endemicity in Indonesia in 2010. PLoS One. 2012;7(5):e37325.
25. Baird JK. Resistance to therapies for infection by Plasmodium vivax. Clin Microbiol Rev. 2009;22:508-34.
26. Matts JP, Lachin JM. Properties of permuted-block randomization in clinical trials. Control Clin Trials. 1988;9(4):327-44.
27. Baird JK, Lacy MD, Basri H, Barcus MJ, Maguire JD, Bangs MJ, et al. Randomized, parallel placebo-controlled trial of primaquine for malaria prophylaxis in Papua, Indonesia. Clin Infect Dis. 2001;33:1990-7.
28. Snounou G, Singh B. Nested polymerase chain reaction analysis of Plasmodium parasites. In: Doolan DL, editor. Malaria methods and protocols. Totowa: Humana Press; 2002. p. 189-203.
29. Baird JK. Primaquine as anti-relapse therapy for Plasmodium vivax. Trans R Soc Trop Med Hyg. 1998;92(6):687.
30. Morgenstern H, Kleinbaum DG, Kupper LL. Measures of disease incidence used in epidemiologic research. Int J Epidemiol. 1980;9(1):97-104.
31. Tapia Granados JA. On the terminology and dimensions of incidence. J Clin Epidemiol. 1997;50(8):891-7.
32. Ling J, Baird JK, Fryauff DJ, Sismadi P, Bangs MJ, Lacy M, et al. Randomized, placebo-controlled trial of atovaquone/proguanil for the prevention of Plasmodium falciparum or Plasmodium vivax malaria among migrants to Papua, Indonesia. Clin Infect Dis. 2002;35(7):825-33.
33. Duparc S, Borghini-Fuhrer I, Craft CJ, Arbe-Barnes S, Miller RM, Shin CS, et al. Safety and efficacy of pyronaridine-artesunate in uncomplicated malaria: an integrated analysis of individual patient data from six randomized clinical trials. Malar J. 2013;12:70.
34. World Health Organization. Guidelines for the Treatment of Malaria. 2015. http://apps.who.int/iris/bitstream/10665/162441/1/9789241549127_eng.pdf?ua=1. Accessed 17 June 2015.
35. Baird JK, Hoffman SL. Primaquine therapy for malaria. Clin Infect Dis. 2004;39(9):1336-45.
36. John GK, Douglas NM, von Seidlein L, Nosten F, Baird JK, White NJ, et al. Primaquine radical cure of Plasmodium vivax: a critical review of the literature. Malar J. 2012;11:280.
37. Collins WE, Jeffery GM. Primaquine resistance in Plasmodium vivax. Am J Trop Med Hyg. 1996;55(3):243-9.
38. Pybus BS, Marcsisin SR, Jin X, Deye G, Sousa JC, Li Q, et al. The metabolism of primaquine to its active metabolite is dependent on CYP 2D6. Malar J. 2013;12:212.
39. Bennett JW, Pybus BS, Yadava A, Tosh D, Sousa JC, McCarthy WF, et al. Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria. N Engl J Med. 2013;369(14):1381-2.
40. Khim N, Benedet C, Kim S, Kheng S, Siv S, Leang R, et al. G6PD deficiency in Plasmodium falciparum and Plasmodium vivax malaria-infected Cambodian patients. Malar J. 2013;12:171.
41. Nacher M, Stefani A, Basurko C, Lemonnier D, Djossou F, Demar M, et al. The burden of Plasmodium vivax relapses in an Amerindian village in French Guiana. Malar J. 2013;12:367.
42. Baird JK. Point of care G6PD diagnostics for Plasmodium vivax malaria is a clinical and public health urgency. BMC Med. doi: 10.1186/s12916-015-0531-0.
43. Khantikul N, Butraporn P, Kim HS, Leemingsawat S, Tempongko MA, Suwonkerd W. Adherence to antimalarial drug therapy among vivax malaria patients in northern Thailand. J Health Popul Nutr. 2009;27(1):4-13.
44. Ingram RJ, Crenna-Darusallam C, Soebianto S, Noviyanti R, Baird JK. The clinical and public health problem of relapse despite primaquine therapy: case review of repeated relapses of Plasmodium vivax acquired in New Guinea. Malar J. 2014;13:488.